ClinicalTrials.gg
RecruitingNCT05366153REDEEM-CADUpdated Dec 4, 2025

Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer

An observational study in Coronary Artery Disease, sponsored by Baker Heart and Diabetes Institute. Recruiting at 2 sites in Australia. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Baker Heart and Diabetes Institute · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
748
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Coronary Artery Disease with a site in Australia — 11 open to participants now, 17 under way, 4 of them phase 3. Coronary Artery Disease · Australia.

Started
2023
with 4 others
Observational
7 of 89
3 open now
Primary completion
2026-05
later than 1 of 16 live
Registered
78th of 89
by date
Lead sponsor
3 of 89
Baker Heart and Diabetes Institute

Among the 89 studies in Coronary Artery Disease with a site in Australia, this one is one of 5 that started in 2023, is one of 7 observational ones, reaches primary completion later than 1 of the 16 other live ones, and was the 78th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

11 of the 89 studies in Coronary Artery Disease with a site in Australia are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Coronary Artery Disease with a site in Australia, or all of them as a file.
02

Study summary

REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago.

Read the detailed description

REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago. The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD. This unique Screening/Management Plan (SMP) has 2 components; 1) A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2) A clinical review to ensure optimal risk factor control and cardio protection.

Follow-up of treated patients will continue for an average of 36 months, with clinic reviews at 12, 24 and 36 months. The results will define the prevalence of subclinical coronary artery disease, and the feasibility and the efficacy of the SMP.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A history of cancer >5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).

Exclusion criteria

Exclusion Criteria:

  • Unable to provide written to participate in this study
  • Known coronary artery disease at recruitment
  • History of previous coronary artery disease
  • Inability to acquire interpretable CT images
  • /Intolerance to or already taking statin therapy
  • Oncologic (or other) \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
748 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Survivor Screening/Management Plan

    In cancer survivors; 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.

    Diagnostic Test: Coronary CT

  • Non-cancer Screening/Management Plan

    In matched non-cancer patients (from EDCAD trial); 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.

    Diagnostic Test: Coronary CT

Interventions

  • Diagnostic testCoronary CT

    Screening/Management Plan

06

What researchers measure

Primary outcomes

  1. Proportion of evaluated patients who should undergo CAD prevention

    High clinical risk, or intermediate risk with CAC score \>0

    Time frame: 3 years

Secondary outcomes

  1. Proportion with critical CAD

    Coronary stenosis \>70% by CT coronary angiogram

    Time frame: 3 years

  2. Proportion at intermediate clinical risk

    Intermediate clinical risk (0.8-2.0% annualized risk by Pooled Cohort Equation)

    Time frame: 3 years

  3. Statin responsiveness

    Change in plaque volume

    Time frame: 3 year follow-up

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Soh CH, Smith J, Shrestha S, Nolan M, Wong J, Nerlekar N, Marwick TH. Screening for coronary artery disease among cancer survivors: rationale and design of the REDEEM-CAD study. Cardiooncology. 2025 Feb 4;11(1):10. doi: 10.1186/s40959-025-00308-7. PubMed 39905553 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for May 2026, 31 months after the start.

Of 636 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 31 months is below that.

Counting every sponsor, half of 761 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 9, 2022
StartActual
Oct 18, 2023
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05366153
Lead sponsor
Baker Heart and Diabetes Institute
Collaborators
Western Health, Australia, Northern Hospital, Australia, Menzies Institute for Medical Research, Peter MacCallum Cancer Centre, Australia, The Alfred
Responsible party
Sponsor
First posted
May 9, 2022
Start date
Oct 18, 2023
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Dec 4, 2025

Study contacts

Tom Marwick, MBBS,PhD,MPH
Contact
tom.marwick@baker.edu.au
+61 3 8532 1550
Lisa Riddell
Contact
lisa.riddell@baker.edu.au
+61 3 8532 1550
Tom Marwick, MBBS,PhD,MPH
principal investigator · Baker Heart and Diabetes Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion